Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients

Beloved Oncologist Dr. Philip D. Bonomi to Retire June 30, 2022

Reflections on Nearly 50 Years in Oncology

More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors

NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition

In Brief for October 12, 2022

Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice

When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience

HER2 Mutations Present Unique Challenges in NSCLC

Targeted Therapies Expanding for MET Dysregulation in NSCLC

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?